Navigation Links
Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Date:2/11/2008

r survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release anticipating future clinical and business prospects for our lead drug candidate Sulonex, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: the results of the Phase 3 study for Sulonex could be inconclusive or negative; even if we receive positive results from the Phase 3 study for Sulonex, we may not be able to finalize the NDA before year end for various reasons including the completion of necessary non- clinical studies; the completion of manufacturing preparations; or other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

Keryx Contact:

Lauren Fischer

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
4. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
(Date:12/22/2014)... 2014  Mark Farrah Associates (MFA), www.markfarrah.com ... of the 2015 marketplace exchange projections and insights ... According to a recent ASPE (Office of ... of Health and Human Services) report, an estimated ... plans through the Marketplace as of October 2014 ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... N.C., Oct. 26 WomanCare Global is pleased ... portfolio to include Roselle®, a combined oral contraceptive ... and 30 micrograms of ethinylestradiol and Optinor®, a ... micrograms of levonorgestrel. (Logo: ...
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... presenting at the Oppenheimer 21st Annual Healthcare Conference in New ... on Tuesday, November 2, 2010 at 11:25 a.m. Eastern Time ... and may be accessed on the Company,s website at ...
Cached Medicine Technology:WomanCare Global Acquires 2 Global Brands From ICON -- Combined Oral Contraceptive Roselle® and Emergency Contraceptive Optinor® 2
(Date:12/25/2014)... Aliso Viejo, California (PRWEB) December 25, 2014 ... the release of ProFire 5k. A fully customizable business ... X . , “Adding the ProFire 5k business tool, ... style” Said Christina Austin, CEO of Pixel Film Studios. ... the look and style to add professionalism to a ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in ... the holiday season, AlignLife looks forward to their annual toy ... Sara Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as ... are able to give kids toys for Christmas who would ... generosity of our patients." , The 70 toys were donated ...
(Date:12/24/2014)... December 25, 2014 Epigenetics finds applications ... research, including oncology, drug discovery, developmental biology, and research ... as one of the most widely used techniques for ... GLOBOCAN, the prevalence of cancer is rapidly growing worldwide. ... 8.2 million cancer deaths, and 32.6 million people living ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... . All these items are brand new; they are made ... updated with the new range of high quality prom gowns. ... iFitDress.com’s designs are made according to the latest trends. For ... outfit from the company is handpicked by skilled tailors. , ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... the University of Aberdeen in the UK say in a ... linked to increased risk of asthma in kids//. The study ... team showed that low vitamin E in mothers was linked ... ,In this study researchers followed 1,000 children at five years. ...
... village died after eating wild poisonous mushrooms while their mother ... Begma, 8, Neelma, 5, and Jaywanti, 2, died Friday in ... here. ,All the children fell unconscious and died ... 30, managed to survive but is still recovering from food ...
... improve donor lung quality as part of the San ... number of available donor lungs and transplant procedures without ... survival. ,The study appears in the second ... Respiratory and Critical Care Medicine, published by the American ...
... Carolina Wilmington announce the continuation of funding to study ... ultimately// yield treatments. The National Institute of Environmental Health ... to further delve into the acute and chronic effects ... Florida's west coast. ,"Preliminary studies with red ...
... in the Sun's brightness over the past millennium have ... to a review of existing results and new calculations// ... Germany. ,The review, led by Peter Foukal (Heliophysics, ... Among the coauthors is Tom Wigley of the National ...
... the inner lining of the nose are linked to ... current treatments according// to researchers at John Hopkins University. ... the misery of persistent inflammation of the moist tissue ... is clogged passages and recurring infections, according to the ...
Cached Medicine News:Health News:Upgrading Donor Lung Quality to Improve Availability 2Health News:Upgrading Donor Lung Quality to Improve Availability 3Health News:"Beach to Bedside" Study Focuses on Effects of Inhaled Toxins 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 2Health News:Changes in Solar Brightness Too Weak to Explain Global Warming 3Health News:Chronic Sinusitis Resulting From Weakene Immune System 2Health News:Chronic Sinusitis Resulting From Weakene Immune System 3
...
...
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Medicine Products: